Aquestive Therapeutics, Inc. · NASDAQ:AQST
Aquestive Therapeutics — H.C. Wainwright 26th Annual Global Investor Conference (September 2024)
28 slides from Aquestive Therapeutics's conference presentation, Sep 9, 2024
Slide 1: H.C. Wainwright 26th Annual Global Investor Conference
Advancing medicines. Solving problems. Improving lives. 1 Advancing medicines. Solving problems. Improving lives. H.C. Wainwright 26th Annual Global Investor Conference September 9, 2024
Slide 2: Disclaimer
Advancing medicines. Solving problems. Improving lives. Disclaimer 2 © 2024 Aquestive Therapeutics, Inc. This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive”, the “Company”, “our” or “us”) and contains forward-looking statements withi
Slide 3: Who we are
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. 3 A publicly traded pharmaceutical company (NASDAQ: AQST) focused on advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolo
Slide 4: PharmFilm drug delivery and Adrenaverse prodrug platform
Advancing medicines. Solving problems. Improving lives. PharmFilm® 4 Drug delivery technologies AdrenaverseTM Prodrug Platform Adrenaverse platform contains a library of over 20 epinephrine prodrugs that demonstrate control of absorption and conversion rates across a variety of dosage forms and deli
Slide 5: Company key facts
6 $50M+ of revenue in 2023 150+ employees based in Indiana and New Jersey More than 2 billion PharmFilm® doses shipped worldwide 19+ years since the company was founded Products are available on 6 continents Over $1.5 billion1 in potential peak annual net sales from pipeline assets (NASDAQ: AQST) 2
Slide 6: Diversified pipeline
Diversified pipeline 6 1. Annual revenue includes revenue for patients 12 and up after launch in 2027. 2. Aquestive Therapeutics data on file.
Slide 7: Growth plan
Advancing medicines. Solving problems. Improving lives. Growth plan 7 1. Assumes satisfaction of all predetermined clinical endpoints and approved by U.S. Food and Drug Administration (FDA). 2. Estimate is based on an orphan drug market exclusivity block until January of 2027 by an FDA approved nasa
Slide 8: Dedicated and experienced leadership team
Advancing medicines. Solving problems. Improving lives. Dedicated and experienced leadership team 8 Daniel Barber President, CEO & Director Lori J. Braender Chief Legal Officer, Chief Compliance Officer, Corporate Secretary Ernie Toth Chief Financial Officer Peter Boyd SVP, HR & IT Mark Schobel Chie
Slide 9: Anaphylaxis: a potentially fatal allergic reaction
Advancing medicines. Solving problems. Improving lives. Anaphylaxis: a potentially fatal allergic reaction1 1. Turner PJ, et al. World Allergy Org J. 2019;12100066. Severe systemic hypersensitivity allergic reaction that is rapid in onset and can cause death Poses serious consequences for at-risk pa
Slide 10: During an allergic reaction, time is the enemy
Advancing medicines. Solving problems. Improving lives. During an allergic reaction, time is the enemy Anaphylaxis signs & symptoms (minutes to hours)1,2 Allergen exposure Li ke lih o o d o f O cc u rr en ce Initial Reaction 5m 10m 15m 20m 25m 30m 1h 8h 72h2h 3h 4h 5h 6h 7h 9h 10h 1. Sampson HA et a
Slide 11: U.S. market has the potential to grow to ~$2B by 2031
Advancing medicines. Solving problems. Improving lives. 11 U.S. market has the potential to grow to ~$2B in value by 20311 1. Aquestive Therapeutics data on file, scripts written for Epinephrine Auto-Injectors have increased at a 15% Compound Annual Growth Rate (CAGR) from 2021- 2023. 2. https://foo
Slide 12: What is happening in the allergy rescue space
Advancing medicines. Solving problems. Improving lives. 12 What is happening in the allergy rescue space • Epinephrine, the only medication proven to stop a life-threatening allergic reaction, is the first-line treatment for anaphylaxis • No oral products are available • By nature, EMDs would be put
Slide 13: Epinephrine medical devices carry rates are low
Advancing medicines. Solving problems. Improving lives. Epinephrine medical devices (EMDs) carry rates are low 13 1. Fromer L. The American Journal of Medicine (2016);129, 1244-1250; data reflects carry rates for autoinjectors only. of patients surveyed who had previously experienced anaphylaxis had
Slide 14: Reasons people don't carry their epinephrine devices
Advancing medicines. Solving problems. Improving lives. Most common reasons that people don’t carry their epinephrine medical devices (EMDs)1 • Inconvenience • Forgetfulness • Cost • Availability at other places, such as the home, car or school • Expiration of the previous prescription • Complacency
Slide 15: DoorDash survey
Advancing medicines. Solving problems. Improving lives. 15 DoorDash® survey1 • The average person has to return home to retrieve four forgotten items per month • 39% of people forget more than five items each month 1. https://nypost.com/2022/07/05/this-many-americans-forget-their-phones-more-before-
Slide 16: Complacency in carrying an EMD is the norm
Advancing medicines. Solving problems. Improving lives. Complacency in carrying an EMD is the norm 1. https://www.healio.com/news/allergy-asthma/20231211/customer-discovery-reveals-why-patients-do-not-carry-their-epinephrine-autoinjectors; survey results reflect autoinjectors only A recent published
Slide 17: Sherry Korczynski, SVP, Sales & Marketing
Advancing medicines. Solving problems. Improving lives. 17 Sherry Korczynski SVP, Sales & Marketing
Slide 18: Anaphylm (epinephrine) sublingual film
Anaphylm (epinephrine) sublingual film + + Easy To Carry Easy To Administer Works Quickly1 18 1. Aquestive Therapeutics data on file. First and only non-device based, orally delivered epinephrine product candidate
Slide 19: Autoinjectors vs Neffy vs Anaphylm
1. KOL feedback; Aquestive Market Research; 2. Warren et al. Ann Allergy Asthma Immunol (2018). 3. Brooks et al. Ann Allergy Asthma Immunol (2017); 4. Asthma and Allergy Foundation of America Patient Survey Report (2019). 5. EpiPen® package insert. 6. neffy prescribing information and clinical studi
Slide 20: Fast-acting and well-tolerated, safety comparable to standard of care
Fast-acting and well-tolerated, with a safety profile comparable to standard of care (SOC)1 20 1 2 3 Rapid absorption as demonstrated by: Consistent pharmacokinetics (PK) demonstrated across 5 administration procedures: Consistent time to peak drug concentration (Tmax) of 12-15 minutes Onset of phar
Slide 21: High epinephrine prescribing physicians have spoken
High epinephrine prescribing physicians have spoken1 21 expressed concern that their at-risk patients don’t consistently have an epinephrine auto injector (EAI) with them when away from home~90% articulated that “a sublingual film is more likely to be carried, thereby protecting more at-risk patient
Slide 22: Planned Anaphylm launch strategy
Planned Anaphylm launch strategy 22 Focus on driving awareness among allergists and pediatricians1 2 3 4 Launch into the “warm weather” volume increase Price within the range of existing standards of care Leverage existing commercial infrastructure
Slide 23: Epinephrine prescribers: an addressable market opportunity
Epinephrine prescribers: an addressable market opportunity1 23 1. Aquestive Therapeutics data on file. 2 • Allergists are the most productive segment by far, averaging ~200 prescriptions per year • Pediatricians are the second most productive segment, averaging ~16 prescriptions per year
Slide 24: Launch into the warm weather volume increase
Launch into the “warm weather” volume increase1 24 1. Aquestive Therapeutics data on file; all market data is limited to U.S. and its Territories.
Slide 25: Price within the current range of existing SOCs
Price within the current range of existing SOCs1 25 1. Aquestive Therapeutics data on file; all market data is limited to U.S. and its Territories.
Slide 26: Leveraging our Libervant experience
Leveraging our Libervant experience 26 Pharmacovigilance Market access Medical affairs Sales leadership Distribution agreements Existing payer contracts Training/HR/Fin/IT Regulatory track record Existing and growing sales and marketing organization¹ 1. Libervant (diazepam) Buccal Film FDA approved
Slide 27: Anaphylm summary
Anaphylm summary 27 1. Aquestive Therapeutics data on file. 2. Scripts written for Epinephrine Auto-Injectors have increased at a 15% Compound Annual Growth Rate (CAGR) from 2021- 2023. Large Market Opportunity Novel Oral Product Late-Stage Development
Slide 28: Thank You
Advancing medicines. Solving problems. Improving lives. 28 Thank You